Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
about
International Consensus Document (ICON): Common Variable Immunodeficiency DisordersImproving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatmentSplice-correction strategies for treatment of X-linked agammaglobulinemia.Fertility, pregnancies and outcomes reported by females with common variable immune deficiency and hypogammaglobulinemia: results from an internet-based surveySafety of L-proline as a stabilizer for immunoglobulin products.Agammaglobulinemia: causative mutations and their implications for novel therapies.Polyvalent immunoglobulins: challenges and perspectivesImmunoglobulin replacement therapy for primary immunodeficiencies.Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery.Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation.Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.Primary Immunodeficiency Diseases: Current and Emerging Therapeutics.A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.Disseminated bronchiectasis in an adult with common variable immunodeficiency.Genetic, Cellular and Clinical Features of ICF Syndrome: a French National Survey.Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses.Is there a need to redefine the diagnostic criteria for common variable immunodeficiency?Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.Hemolysis in patients with antibody deficiencies on immunoglobulin replacement treatment.
P2860
Q26777304-A6D6ABC2-D384-4EDA-AB69-EF1C8E0F53C2Q33583520-F0A6AF04-BE82-4B39-9C55-5E5A20274FC5Q35033817-5F29D695-C1F9-4E0A-9A0E-9AFE43A97BA5Q35155252-F986BCBC-8FDC-4E09-8E95-26897B13E7FBQ37979844-B3AFC3C8-5E91-4BFB-A417-29D23238D838Q38161559-F74A95B3-D853-4EAC-92BE-3935D1651277Q38170873-557A0E64-072C-4C6C-8BED-4B2A3F38F5C7Q38257643-341894BE-C00C-4A73-9512-9A05278A9058Q38398798-CFCB4150-AF27-4215-B415-D8C5808DB8FDQ38420971-E8EFEF23-529D-4183-8BA1-A5CCF5954351Q40045651-1AF122F3-E20D-42BA-8281-9B698E001F02Q40076704-FA7C7929-3027-42AD-9A31-93731D1647FEQ40133456-DF02E0BB-0244-4FEB-935A-B830DB910B58Q40154117-44F2B14D-6609-404F-A1F1-5062ADCADB3AQ40802055-66161125-F7ED-4772-B7DD-475CD97009F0Q40994858-7F714F50-23CB-4B36-B9E0-13553C81368AQ44772565-FE00B957-274E-45D8-BC79-445345367717Q48302996-F0DA4387-A84C-45AC-89E4-A9B577C8A872Q50454680-BF964631-C975-4B2F-927D-4298D2D9DCF8
P2860
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@en
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@nl
type
label
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@en
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@nl
prefLabel
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@en
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@nl
P2860
P1476
Key aspects for successful immunoglobulin therapy of primary immunodeficiencies.
@en
P2093
C Cunningham-Rundles
P2860
P356
10.1111/J.1365-2249.2011.04390.X
P478
164 Suppl 2
P577
2011-06-01T00:00:00Z